ATE499090T1 - Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan - Google Patents

Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan

Info

Publication number
ATE499090T1
ATE499090T1 AT07726012T AT07726012T ATE499090T1 AT E499090 T1 ATE499090 T1 AT E499090T1 AT 07726012 T AT07726012 T AT 07726012T AT 07726012 T AT07726012 T AT 07726012T AT E499090 T1 ATE499090 T1 AT E499090T1
Authority
AT
Austria
Prior art keywords
telmisartan
pharmaceutical composition
composition containing
hydrochlorothiazide
containing hydrochlorothiazide
Prior art date
Application number
AT07726012T
Other languages
German (de)
English (en)
Inventor
Adnan Beso
Igor Legen
Sebastjan Reven
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37222308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE499090(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Application granted granted Critical
Publication of ATE499090T1 publication Critical patent/ATE499090T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT07726012T 2006-06-16 2007-06-14 Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan ATE499090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012381 2006-06-16
PCT/EP2007/005248 WO2007144175A2 (fr) 2006-06-16 2007-06-14 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
ATE499090T1 true ATE499090T1 (de) 2011-03-15

Family

ID=37222308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07726012T ATE499090T1 (de) 2006-06-16 2007-06-14 Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan

Country Status (8)

Country Link
US (2) US8685452B2 (fr)
EP (2) EP2269583B1 (fr)
AT (1) ATE499090T1 (fr)
CA (2) CA2654890C (fr)
DE (1) DE602007012692D1 (fr)
ES (1) ES2523729T3 (fr)
SI (1) SI2269583T1 (fr)
WO (1) WO2007144175A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
US20100247649A1 (en) 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
SI2252273T1 (sl) 2008-03-19 2017-06-30 Ratiopharm Gmbh Trdni farmacevtski sestavek, ki obsega nepeptidni antagonist receptorja angiotenzina II in diuretik
WO2009135646A2 (fr) * 2008-05-05 2009-11-12 Farmaprojects, Sa Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2210595A1 (fr) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Revêtement actif de formes de dosage pharmaceutique
DK2396005T3 (da) 2009-02-13 2026-02-09 Boehringer Ingelheim Int Sglt2 hæmmer til at forbedre glykæmisk kontrol
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
ES2415357T3 (es) 2009-06-19 2013-07-25 Krka Tovarna Zdravil, D.D., Novo Mesto Procedimiento para la preparación de telmisartán
CN101632678B (zh) * 2009-09-01 2011-09-14 严洁 一种氯沙坦钾氢氯噻嗪组合物及其制备方法
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
EA020798B1 (ru) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
WO2011161123A2 (fr) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Comprimé pharmaceutique multicouche comprenant du telmisartan et un diurétique
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP2612658A1 (fr) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Compositions pharmaceutiques d'acide 4'-[(1,4'diméthyl-2'-propyl[2,6'-BI-1H-benzimidazol]-1'-YL)méthyl]-[1,1'-biphényl]-2-carboxylique et IS 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxyde
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR101414873B1 (ko) * 2012-06-28 2014-07-03 보령제약 주식회사 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
EP4678242A3 (fr) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Composition pharmaceutique, procédés de traitement et utilisations de celle-ci
CN105560209B (zh) * 2016-01-25 2019-03-29 苏州中化药品工业有限公司 一种治疗心血管疾病的复方制剂及其制备方法
KR20190084096A (ko) 2016-11-10 2019-07-15 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
US11826473B2 (en) * 2018-01-11 2023-11-28 Sawai Pharmaceutical Co., Ltd. Orally disintegrating tablet coated with film
CN117257769A (zh) * 2023-10-11 2023-12-22 珠海润都制药股份有限公司 一种替米沙坦微丸及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444769A (en) 1982-07-27 1984-04-24 Mylan Pharmaceuticals, Inc. Antihypertensive diuretic combination composition and associated method
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US20050020671A1 (en) * 2001-02-14 2005-01-27 Matilde Fernandez Ibanez Pharmaceutical formulation
UA78542C2 (en) 2002-01-15 2007-04-10 Actavis Group Hf Formulations of quinapril and other ace inhibitors
BR0215514A (pt) 2002-01-16 2004-12-21 Boehringer Ingelheim Pharma Comprimido farmacêutico de bicamada compreendendo telmisartan e um diurético e preparação deste
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
KR101137084B1 (ko) 2003-10-10 2012-04-24 애보트 프러덕츠 게엠베하 셀렉티브 ⅰ１ 이미다졸린 수용체 작용제 및 엔지오텐신 ⅱ수용체 차단제를 포함하는 약학적 조성물
WO2005082329A2 (fr) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Procede de preparation de formes posologiques solides de valsartan et d'hydrochlorthiazide
DE102004008804A1 (de) 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
CA2795729C (fr) * 2010-04-05 2015-12-08 Polytechnic Institute Of New York University Compositions d'analogues de sophorolipides

Also Published As

Publication number Publication date
EP2029112B2 (fr) 2014-02-19
CA2836545A1 (fr) 2007-12-21
WO2007144175A2 (fr) 2007-12-21
EP2269583B1 (fr) 2014-08-13
EP2269583A1 (fr) 2011-01-05
DE602007012692D1 (de) 2011-04-07
CA2836545C (fr) 2016-08-09
EP2029112A2 (fr) 2009-03-04
EP2029112B1 (fr) 2011-02-23
SI2269583T1 (sl) 2014-12-31
ES2523729T3 (es) 2014-12-01
US20140134247A1 (en) 2014-05-15
WO2007144175A3 (fr) 2008-10-02
US20090202636A1 (en) 2009-08-13
CA2654890C (fr) 2015-10-06
CA2654890A1 (fr) 2007-12-21
US9622976B2 (en) 2017-04-18
US8685452B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
ATE499090T1 (de) Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
EP2054036A4 (fr) Formulation de nanoparticules solides de substances pharmaceutiques insolubles dans l'eau avec mûrissement d'ostwald réduit
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
CR20110609A (es) Composicion antimicrobiana y metodos relacionados de uso
EP2004172A4 (fr) Méthodes d'administration de médicaments, structures et compositions utilisées dans le système nasolacrymal
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
EP2037917A4 (fr) Composition pharmaceutique comprenant de l'amlodipine et du losartan
CR10769A (es) Improvements in and relating to drive mechanisms suitable for use in drug delicery devices
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CR9355A (es) Formulacion farmaceutica novedosa que contiene una biguanida y un derivado de tiazolidinadiona
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
EP2123276A4 (fr) Composition pharmaceutique comportant un dérivé de pyrazine et procédé d'utilisation d'un dérivé de pyrazine en combinaison
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
ITFI20050042A1 (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
CR9703A (es) Derivados de pirazolona
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
SI1744756T1 (sl) Uporaba meloksikamskih formulacij v veterinarski medicini

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2029112

Country of ref document: EP